

ARC '16

مؤتمر مؤسسة قطر
السنوي للبحوث
QATAR FOUNDATION
ANNUAL RESEARCH
CONFERENCE


مؤسسة قطر
Qatar Foundation
إطلاق قدرات الإنسان.
Unlocking human potential

Towards World-class
Research and Innovation

Health and Biomedical Pillar

<http://dx.doi.org/10.5339/qfarc.2016.HBPP3347>

Synthesis, Characterization, Crystal Structures, and in vitro Antitumor Activity of Palladium and Platinum (II) Complexes with 2-Acetyl-4-Methylthiazole Thiosemicarbazone and 2-Acetylpyrazine Thiosemicarbazone

Hassan Nimir¹, Norah Al Mohaideb¹, Mariem Hamad¹, Awadelkareem Ali², Cenk Aktas², Volker Huch³, Michael Veith^{2,3}, Uli Rauch⁴

¹Department of Chemistry and Earth Sciences, College of Arts and Sciences, Qatar University, P.O. Box 2713, Doha, State of Qatar

²INM-Leibniz Institute for New Materials, Campus D2 2, 66123 Saarbrücken, Germany

³Institute of Inorganic Chemistry, Saarland University, D-66041, Saarbrücken, Germany

⁴University of Zweibrücken for Applied Science and Technology, Zweibrücken, Germany

Email: hnimir@qu.edu.qa

Abstract

The novel Schiff bases I HAMTTSC (2-Acetyl-4-methylthiazole thiosemicarbazone), II HAPTSC(2-Acetylpyrazine thiosemicarbazone) and their complexes with Pt(II) and Pd(II): 1 [Pt(AMTTSC)Cl], 2 [Pt(AMTTSC)2], 3 [Pd(AMTTSC)Cl], 4 [Pd(AMTTSC)2], 5 [Pt(APTSC)Cl], 6 [Pt(APTSC)2], 7 [Pd(APTSC)Cl], and 8 [Pd(APTSC)2] have been synthesized, and characterized by elemental analysis and spectroscopic studies. The crystal structure of the Schiff bases I, II, and the complex 1 [Pt(AMTTSC)Cl], have been solved by single-crystal X-ray diffraction. The electronic, IR, UV/Vis, and NMR spectroscopic data of I and II and their complexes are reported. The in vitro antitumor activity of the Schiff bases and 1, 2, 4, 5 and 6 complexes against two different human tumor cell lines (HT-29 and HuTu-80) reveals that the complexes are more cytotoxic than their corresponding ligands with IC50 values at the range of 0.1–10 µM. These compounds can therefore be considered as agents with potential antitumor activity.

Molecular structure of 1 [Pt(AMTTSC)Cl]

Cite this article as: Nimir H, Al Mohaideb N, Hamad M, Ali A, Aktas C, Huch V, Veith M, Rauch U. (2016). Synthesis, Characterization, Crystal Structures, and in vitro Antitumor Activity of Palladium and Platinum (II) Complexes with 2-Acetyl-4-Methylthiazole Thiosemicarbazone and 2-Acetylpyrazine Thiosemicarbazone. Qatar Foundation Annual Research Conference Proceedings 2016: HBPP3347 <http://dx.doi.org/10.5339/qfarc.2016.HBPP3347>.

Introduction

Thiosemicarbazones (TSCNs) are very promising molecules in coordination chemistry because of their pharmacological properties of both ligands and complexes, (1–3) which include notably their antiparasitic, (4) antibacterial (5, 6) and antitumor activities (7) depending on the parent aldehyde and ketone and, of course, metal ion. The thiosemicarbazone ligand usually coordinates with a metal through the imine nitrogen and the sulphur atom forming a five-membered ring chelate. Since cis-platin emerged as the most important antitumor drug (8), thousands of metal complexes have been synthesized and characterized in order to study the effect of the metal, the attached group on the structural and kinetic properties involved in the biological activity. (9) However significant problems are still extant, including side effects, toxicity, cancer specificity and acquired resistance. Consequently the development of new compounds outside the usual coordination sphere or of different structural properties is the challenge to cancer research.

Synthesis of the ligands

The ligands 2-Acetyl-4-methylthiazole thiosemicarbazone and 2-acetylpyrazine thiosemicarbazone, were prepared according to the literature (10).

Synthesis of Complexes Pt (AMTTSC)Cl Complex

A solution of K_2PtCl_4 (0.208 g, 0.5 mmol) in methanol, was added dropwise to a stirred solution of HAMTTSC (0.5 mmol) in 20 mL of methanol. The solution was refluxed for 2 hours and stirred for 24 hours at room temperature. The dark red precipitate was collected by filtration and dried in vacuo. Crystals suitable for X-Ray diffraction were obtained through slow evaporation of the DMF solvent.

Solid, yield: 70.59%, m.p. 236–237°C. Anal. Calc. For $Pt(C_7H_9N_4S_2)Cl$ (443.84 g/mol): C, 18.94%; H, 2.04%; N, 12.62%. Found: C, 18.74%; H, 2.18%; N, 12.85%. I.R. (solid state, cm^{-1}): $\nu(NH_2)$ 3395, 3267; $\nu(C=N)$ 1520.38; $\nu(C=S)$ 873.31; $\nu(N-N)$ 1065.89. $^1H-N.M.R.$ (DMSO- d_6): δ 2.21, 2.41 (s, 6H, 2CH₃), 7.75 (s, 1H); 8.07(b, 2H, NH₂). $^{13}C-N.M.R.$ (DMSO- d_6): δ 13.93, 16.39 (2CH₃); 148.59, –154.62(3C ring); 171.92 (HC=N); 183.20 (C=S). Electronic spectra (λ_{max} nm): 270, 391, 531.

Pt (AMTTSC) 2 Complex

A solution of K_2PtCl_4 (0.208 g, 0.5 mmol) in methanol, was added dropwise to a stirred solution of HAMTTSC (1.0 mmol) in 30 mL of methanol. The solution was refluxed for 2 hours and stirred for 24 hours at room temperature. The pinkish red precipitate was collected by filtration and dried in vacuo.

Solid, yield: 74.36%, m.p. dec.>245°C. Anal. Calc. For $Pt(C_7H_9N_4S_2)_2$ (621.69 g/mol): C, 27.05%; H, 2.92%; N, 18.02%. Found: C, 27.01%; H, 3.028%; N, 18.97%. IR (solid state, cm^{-1}): $\nu(NH_2)$ 3354.48, 3265.78; $\nu(C=N)$ 1535.94; $\nu(C=S)$ 873.25; $\nu(N-N)$ 1075.01. $^1H-N.M.R.$ (DMSO- d_6): δ 2.21, 2.39 (s, 6H, 2CH₃), 7.74, 7.34(s, 1H); 8.07 (b, 2H, NH₂); 8.51, (b, 2H, NH₂). $^{13}C-N.M.R.$ (DMSO- d_6): δ 13.51, 16.39 & 13.91, 16.76 (4CH₃); 144.02-152.49 & 148.57-154.64 (3C ring); 166.07 & 171.93 (HC=N); 183.22 (C=S). Electronic spectra (λ_{max} nm): 270, 363, 389, 53.

Pd (AMTTSC)Cl Complex

A solution of K_2PdCl_4 (0.163 g, 0.5 mmol) in methanol, was added dropwise to a stirred solution of HAMTTSC (0.5 mmol) in 20 mL of methanol. The solution was refluxed for 2 hours and stirred for 14 hours at room temperature. The orange precipitate was collected by filtration, washed with ethanol and ether, and dried in vacuo.

Solid, yield: 92.39%. m.p. 236–237°C. Anal. Calc. For $Pd(C_7H_9N_4S_2)Cl$ (355.18 g/mol): C, 23.67%; H, 2.55%; N, 15.77%. Found: C, 22.94%; H, 2.68%; N, 15.09%. IR (solid state, cm^{-1}): $\nu(NH_2)$ 3426.47, 3304.62; $\nu(C=N)$ 1552.37; $\nu(C=S)$ 867.85; $\nu(N-N)$ 1118.21. $^1H-N.M.R.$ (DMSO- d_6): δ 2.25, (s, 6H, 2CH₃), 7.64 (s, 1H); 7.93 (d, 2H, NH₂). $^{13}C-N.M.R.$ (DMSO- d_6): δ 13.83, 16.36 (2CH₃); 145.69, 147.79–154.36(3C ring); 169.58 (HC=N); 180.71 (C=S). Electronic spectra (λ_{max} nm): 274, 313, 386, 493.

Pd(AMTTSC)2 Complex

A solution of Pd(acac)₂ (0.152 g, 0.5 mmol) in CH₂Cl₂/ CH₃OH (30 mL, 2:1 v/v) was added dropwise to a stirred solution of HAMTTSC (1.0 mmol) in 30 mL of methanol. The solution was refluxed for 2 hours and stirred for 24 hours at room temperature. The red precipitate was collected by filtration, washed with ethanol and ether, and dried in vacuo.

Solid, yield: 79.54%. m.p. dec. >174°C. Anal. Calc. For Pd(C₇H₉N₄S₂)₂, (533.03 g/mol): C, 31.55%; H, 3.4%; N, 21.02%. Found: C, 30.77%; H, 3.62%; N, 19.84%. IR (solid state, cm⁻¹): ν(NH₂) 3308.98, 3257.77; ν(C=N) 1557.07; ν(C=S) 871.65; ν(N-N) 1080.62. ¹H-N.M.R. (DMSO-d₆): δ 1.46, 1.62 (s, 6H, 2CH₃), 7.04 (s, 1H); 8.04, 6.74 (d, 2H, NH₂). ¹³C-N.M.R. (DMSO-d₆): δ 13.66, 16.18 (2CH₃); 147.49, 152.70 & 148.44, 155.45 (3C ring); 169.62 & 171.19 (HC=N);, 182.38 (C=S). Electronic spectra (λ_{max} nm): 289, 348, 448.

Conclusion

New potential anti-cancer Pt (II) and Pd(II) complexes were synthesized through the reaction of the heterocyclic thiosemicarbazone ligands with Pt (II) and Pd (II) ions in 1:1 and 1:2 ratios reactions.

The structures of the synthesized compounds were elucidated on the bases of spectroscopic data (IR, ¹H and ¹³C N.M.R, UV-VIS and XRD).

As the experimental results show, the synthesized Schiff bases reacts with Pt(II) ion in different modes of bonding, they react as tridentate through the mercaptide sulfur ion, the azomethine nitrogen atom and the nitrogen of the ring.

All ligand and complexes tested show a concentration dependent reduction of cell proliferation. The test results show that the change of the ligand metal ratio has significant effects on the antiproliferative activities of the platinum(II) complexes. In general, it was found that complexes were more active than the corresponding ligand. The complex with the formula PtLCl was found to be slightly more active than the complexes with formula PtL₂ against HT-29 and HuTu cancer cells line.

References

- (1) Kovala-Demertzi D., Boccarelli A., Demertzis M. A., and Coluccia M., In vitro antitumor activity of 2-acetyl pyridine 4N-ethyl thiosemicarbazone and its platinum(II) and palladium(II) complexes, *Chemotherapy*, (2007), 53,2, 148.
- (2) Kovala-Demertzi D., Varadinova T., Genova P., Souza P., and Demertzis M. A., "Platinum(II) and palladium(II) complexes of pyridine-2-carbaldehyde thiosemicarbazone as alternative antiherpes simplex virus agents, *Bioinorganic Chem. and App*, (2007), 56165, 2007.
- (3) Scovill, J.P., Klayman D.L., Franchino C.F., Acetylpyridine Thiosemicarbazones Complexes with Transition Metals as Antimalarial and Antileukemic Agents. *J. Med. Chem.*, (1982); 25, 1261.
- (4) Duffy K. J., Shaw A. N., Delmore E., Dillon S. B., Erickson-Miller C., Giampa L., Huang Y., Keenan R. M., Lamb P., Liu N., Miller S. G., Price A. T., Rosen J., Simth H., Wiggall K. J., Zhang L, Luengo J. I., *J. Med. Chem.*, (2002), 45, 3573.
- (5) Agarwal R. K., Singh L., and Sharma D. K., Synthesis, spectral, and biological properties of copper(II) complexes of thiosemicarbazones of Schiff bases derived from 4-aminoantipyrine and aromatic aldehydes, *Bioinorg. Chem. and Appl.*, (2006), 59509, 2006.
- (6) Pandey O. P., Sengupta S. K., Mishra M. K., and Tripathi C. M., Synthesis, spectral and antibacterial studies of binuclear titanium(IV)/zirconium(IV) complexes of piperazine dithiosemicarbazones, *Bioinorg. Chem. and Appl*, (2003), 1., 1, 35.
- (7) Quiroga A. G., P´erez J. M., L´opez-Solera I., et al., Novel tetranuclear orthometalated complexes of Pd(II) and Pt(II) derived from p isopropylbenzaldehyde thiosemicarbazone with cytotoxic activity in cis-DDP resistant tumor cell lines. Interaction of these complexes with DNA, *J. of Med. Chem*, (1998), 41, 9, 1399.
- (8) Smith J. E., Talbot D. C., *Ber. J. Cancer*, (1991), 65, 787.
- (9) Hacker M. P., Khokar A. R., Brown D. B., McCormack J. J., Krakoff J. M., *Cancer Res*, (1985), 45, 4748.
- (10) De Lima G.M., Neto J.L., Beraldo H., Seibald H.G.L, Duncalf D.J., *J. of Molec. Struc.* (2001), 604, 287.